This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Connerotte, T. Articles by Coulie, P. G. Search for Related Content PubMed PubMed Citation Articles by Connerotte, T. Articles by Coulie, P. G.

Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities

¹ de Duve Institute, Université Catholique de Louvain, ² Ludwig Institute for Cancer Research, Brussels Branch, ³ Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of Vrije Universiteit Brussel, Brussels, Belgium; ⁴ EA 4054, Université René Descartes, Unité d'Immunologie Biologique, Hôpital Européen Georges Pompidou AP-HP, Paris, France; and ⁵ Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany

Requests for reprints: Pierre G. Coulie, de Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels, Belgium. Phone: 32-2764-7581; Fax: 32-2764-7590; E-mail: pierre.coulie{at}uclouvain.be.

Key Words: melanoma • vaccination • MAGE • dendritic cell

Tumor regressions have been observed in a small proportion of melanoma patients vaccinated with a MAGE-A3 peptide presented by HLA-A1, administered as peptide, ALVAC canarypox virus containing a MAGE-A3 minigene, or peptide-pulsed dendritic cells (DC). There was a correlation between tumor regression and the detection of anti–MAGE-3.A1 CTL responses. These responses were monoclonal and often of a very low magnitude after vaccination with peptide or ALVAC, and usually polyclonal and of a higher magnitude after DC vaccination. These results suggested that, at least in some patients, surprisingly few anti–MAGE-3.A1 T-cells could initiate a tumor regression process. To understand the role of these T cells, we carried out a functional analysis of anti–MAGE-3.A1 CTL clones derived from vaccinated patients who displayed tumor regression. The functional avidities of these CTL clones, evaluated in lysis assays, were surprisingly low, suggesting that high avidity was not part of the putative capability of these CTL to trigger tumor rejection. Most anti–MAGE-3.A1 CTL clones obtained after DC vaccination, but not after peptide or ALVAC vaccination, produced interleukin 10. Transcript profiling confirmed these results and indicated that approximately 20 genes, including CD40L, prostaglandin D2 synthase, granzyme K, and granzyme H, were highly differentially expressed between the anti–MAGE-3.A1 CTL clones derived from patients vaccinated with either peptide-ALVAC or peptide-pulsed DC. These results indicate that the modality of vaccination with a tumor-specific antigen influences the differentiation pathway of the antivaccine CD8 T-cells, which may have an effect on their capacity to trigger a tumor rejection response. [Cancer Res 2008;68(10):3931–40]